Safety and Efficacy Study of Intramuscular Uricase-PEG 20
Primary Purpose
Gout, Hyperuricemia
Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Uricase-PEG 20
Sponsored by
About this trial
This is an interventional treatment trial for Gout
Eligibility Criteria
Inclusion Criteria:
- Serum uric acid > 6 mg/dL (men) or > 5 mg/dL (women)
- Clinical laboratory values within normal limits or not clinically significant
- Women should be menopausal or peri-menopausal
Exclusion Criteria:
- Prior exposure to uricase
- History of severe allergic reactions, or any allergy to PEG or pegylated products
- G6PD or catalase deficiency
- Medical condition that may interfere with ability to complete the study (e.g., uncontrolled diabetes or hypertension, congestive heart failure NYHA Class III or IV, history of myocardial infarction, immunosuppression, pregnancy)
Sites / Locations
- MRA Clinical ResearchRecruiting
- Altoona Center for Clinical ResearchRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Uricase-PEG 20
Arm Description
Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
Outcomes
Primary Outcome Measures
Safety (assessment of signs and symptoms and clinical laboratory measurements following administration of Uricase-PEG 20, graded according to the Common Toxicity Criteria for Rheumatology, version 2.0)
Secondary Outcome Measures
Pharmacokinetics (Uricase-PEG 20 serum concentration)
Pharmacodynamics (plasma uric acid concentration)
Immunogenicity
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01038947
Brief Title
Safety and Efficacy Study of Intramuscular Uricase-PEG 20
Official Title
A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20
Study Type
Interventional
2. Study Status
Record Verification Date
December 2009
Overall Recruitment Status
Unknown status
Study Start Date
December 2009 (undefined)
Primary Completion Date
April 2010 (Anticipated)
Study Completion Date
May 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
EnzymeRx
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the safety, pharmacokinetics and pharmacodynamics of single and multiple intramuscular doses of Uricase-PEG 20
Detailed Description
Uricase is an enzyme (found in most mammals but not humans) that converts poorly soluble uric acid into highly soluble allantoin. Because humans lack uricase, they are prone to develop elevated levels of uric acid, which can form crystals in the joints and soft tissues. In those which chronically elevated uric acid, gout may develop. In the setting of acute rises in uric acid, seen for example in tumor lysis syndrome, uric acid crystals can damage the renal tubules. Uricase-PEG 20 is a recombinant uricase conjugated with multiple PEG molecules designed to prolong the half-life and decrease the immunogenicity of uricase. This study will characterize the safety, pharmacokinetics and pharmacodynamics of intramuscular Uricase-PEG 20, the anticipated route of administration to be used in future clinical development in gout.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gout, Hyperuricemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
28 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Uricase-PEG 20
Arm Type
Experimental
Arm Description
Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
Intervention Type
Biological
Intervention Name(s)
Uricase-PEG 20
Intervention Description
Intramuscular injection of Uricase-PEG 20 without premedication
Primary Outcome Measure Information:
Title
Safety (assessment of signs and symptoms and clinical laboratory measurements following administration of Uricase-PEG 20, graded according to the Common Toxicity Criteria for Rheumatology, version 2.0)
Time Frame
Up to 35 days after dosing
Secondary Outcome Measure Information:
Title
Pharmacokinetics (Uricase-PEG 20 serum concentration)
Time Frame
Up to 35 days after dosing
Title
Pharmacodynamics (plasma uric acid concentration)
Time Frame
Up to 35 days after dosing
Title
Immunogenicity
Time Frame
Up to 35 days after dosing
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Serum uric acid > 6 mg/dL (men) or > 5 mg/dL (women)
Clinical laboratory values within normal limits or not clinically significant
Women should be menopausal or peri-menopausal
Exclusion Criteria:
Prior exposure to uricase
History of severe allergic reactions, or any allergy to PEG or pegylated products
G6PD or catalase deficiency
Medical condition that may interfere with ability to complete the study (e.g., uncontrolled diabetes or hypertension, congestive heart failure NYHA Class III or IV, history of myocardial infarction, immunosuppression, pregnancy)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rocelle Flores
Phone
201-843-4424
Ext
203
Email
rflores@enzymerx.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony S Fiorino, MD, PhD
Organizational Affiliation
EnzymeRx, LLC
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Patricia Pardo, MD
Organizational Affiliation
MRA Clinical Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
MRA Clinical Research
City
Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vivian Rosales
Phone
305-772-2857
Email
vrosales@miamiresearch.com
First Name & Middle Initial & Last Name & Degree
Patricia Pardo, MD
Facility Name
Altoona Center for Clinical Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ellen Kivitz
Phone
814-693-0300
Ext
224
First Name & Middle Initial & Last Name & Degree
Alan J Kivitz, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
12233890
Citation
Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002 Sep;29(9):1942-9.
Results Reference
background
Links:
URL
http://www.enzymerx.com
Description
Homepage of sponsoring company
Learn more about this trial
Safety and Efficacy Study of Intramuscular Uricase-PEG 20
We'll reach out to this number within 24 hrs